104 related articles for article (PubMed ID: 24330849)
1. Restoration of INK4a/ARF gene inhibits cell growth and cooperates with imatinib mesylate in Philadelphia chromosome-positive leukemias.
Bai Y; Lu Z; Lin Y; Sun B; Wang S; Wang G
Oncol Res; 2013; 21(1):23-31. PubMed ID: 24330849
[TBL] [Abstract][Full Text] [Related]
2. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Williams RT; Roussel MF; Sherr CJ
Proc Natl Acad Sci U S A; 2006 Apr; 103(17):6688-93. PubMed ID: 16618932
[TBL] [Abstract][Full Text] [Related]
3. Expression of the cell cycle regulators p14(ARF) and p16(INK4a) in chronic myeloid leukemia.
Cividin M; Ayrault O; Sorel N; Séité P; Brizard F; Blanchet O; Mahon FX; Guilhot F; Larsen C; Chomel JC; Brizard A
Leuk Res; 2006 Oct; 30(10):1273-8. PubMed ID: 16533530
[TBL] [Abstract][Full Text] [Related]
4. The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Williams RT; Sherr CJ
Adv Exp Med Biol; 2007; 604():107-14. PubMed ID: 17695724
[TBL] [Abstract][Full Text] [Related]
5. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Nimmanapalli R; Fuino L; Stobaugh C; Richon V; Bhalla K
Blood; 2003 Apr; 101(8):3236-9. PubMed ID: 12446442
[TBL] [Abstract][Full Text] [Related]
6. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
7. [Effect of up-regulated expression of tumor suppressor gene p14(ARF) on apoptosis of chronic myeloid leukemia cells].
Bai YS; Liu J; Liu XH; Dai EY; Sun BT; Lu ZX
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):512-5. PubMed ID: 23827110
[TBL] [Abstract][Full Text] [Related]
8. Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase.
Nagy E; Beck Z; Kiss A; Csoma E; Telek B; Kónya J; Oláh E; Rák K; Tóth FD
Eur J Cancer; 2003 Nov; 39(16):2298-305. PubMed ID: 14556920
[TBL] [Abstract][Full Text] [Related]
9. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
10. p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice.
Shank-Calvo JA; Draheim K; Bhasin M; Kelliher MA
Oncogene; 2006 May; 25(21):3023-31. PubMed ID: 16407836
[TBL] [Abstract][Full Text] [Related]
11. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
[TBL] [Abstract][Full Text] [Related]
12. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
Kuroda J; Kimura S; Segawa H; Kobayashi Y; Yoshikawa T; Urasaki Y; Ueda T; Enjo F; Tokuda H; Ottmann OG; Maekawa T
Blood; 2003 Sep; 102(6):2229-35. PubMed ID: 12763930
[TBL] [Abstract][Full Text] [Related]
13. Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate.
Jørgensen HG; Allan EK; Mountford JC; Richmond L; Harrison S; Elliott MA; Holyoake TL
Exp Hematol; 2005 Oct; 33(10):1140-6. PubMed ID: 16219536
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
[TBL] [Abstract][Full Text] [Related]
15. Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.
Carter BZ; Mak DH; Shi Y; Schober WD; Wang RY; Konopleva M; Koller E; Dean NM; Andreeff M
Cell Cycle; 2006 Oct; 5(19):2223-9. PubMed ID: 16969080
[TBL] [Abstract][Full Text] [Related]
16. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
[TBL] [Abstract][Full Text] [Related]
17. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
18. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
19. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.
Williams RT; Sherr CJ
Cold Spring Harb Symp Quant Biol; 2008; 73():461-7. PubMed ID: 19028987
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
